Prostate Cancer

PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.

Talazoparib plus enzalutamide significantly delayed the deterioration of global health status and quality of life in patients with mCRPC in the TALAPRO-2 study.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.

An ARANOTE substudy showed darolutamide plus ADT significantly improved outcomes (rPFS HR 0.51) and PSA suppression in Black men with mHSPC, with similar safety to overall trial.

A study of 47,387 patients found radical prostatectomy had the lowest long-term risk of severe genitourinary complications after localized prostate cancer treatment compared to combination therapies.

Prostatectomy for grade group 1 prostate cancer significantly decreased from 2010 to 2024 in SEER and MUSIC data. Remaining cases show more high-risk features.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic hormone-sensitive prostate cancer.

Sophia Kamran, MD, discusses how salvage therapy after biochemical recurrence may improve outcomes for patients with prostate cancer.

Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.

Colin P.N. Dinney, MD, discusses updated translational analyses from the BOND-003 and CORE-001 trials.

Pedro C. Barata, MD, MSc, discusses the use of darolutamide in patients with hormone-sensitive prostate cancer.

Alexander Kenigsberg, MD, discusses a new nonsurgical, robotic-focused ultrasound procedure for prostate cancer.

Jeffrey Wong, MD, discusses the evolving field of combination therapy with radiopharmaceuticals in prostate cancer.

Jeffrey Wong, MD, discusses the unmet needs in prostate cancer treatment, especially in regard to radiopharmaceuticals.

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant prostate cancer has been dosed.

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic castration-resistant prostate cancer.

The FDA approved 177Lu PSMA-617 for prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer after androgen therapy.

Alan H. Bryce, MD, discusses ongoing research in radioligand therapies.

Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.

A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

TLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.

Cedric Pobel, MD, covers the PEACE-1 trial of radiotherapy, standard of care, and abiraterone in low-volume metastatic castration-sensitive prostate cancer.